Indeed, comparison of different studies about PD-L1 expression in NSCLC is hindered by discrepant issues, including methodologies, thresholds to determine positivity and clinicopathological differences in cohorts36. This evidence concerns the gene CD274 and non-small cell lung carcinoma.